Small Cap Feast
Small Cap Feast – 17 July 2020
Dish of the Day:
No Joiners Today
No Joiners Today
Off the Menu:
No Leavers Today
No Leavers Today
What’s Cooking in the IPO Kitchen?
AEX Gold (TSXV:AEV) is intending to admit its shares to AIM alongside a £45m placing. The Company, led by CEO Eldur Ólafsson, has established the largest land package of gold assets in Greenland with a current portfolio of licences covering 3,356 square kilometres, in the two known gold belts in Southern Greenland, the Nanortalik and Tartoq gold belts. Nalunaq is a high-grade gold asset with an updated Inferred Mineral Resource covering 422,770 tonnes at 18.5 grams per tonne of gold, or 250,970 ounces of gold, which covers the area in and around the historical mine. Due July. Current mkt cap C$66.7m.
Remote Monitored Systems 0.275p £1.82m (RMS.L)
RMS has entered into an exclusivity arrangement and agreed outline non-binding heads of terms in respect of a potential acquisition of a company that operates in the fast growing medtech and biosecurity sectors.
The consideration for the proposed acquisition, should it proceed, is expected to be satisfied by the issue of new Ordinary Shares in the Company. The acquisition is subject, inter alia, to the completion of mutual due diligence by both parties and there can be no certainty that a transaction will proceed
ClearStar 37p £13.45m (CLSU.L)
The provider of Human Capital Integrity℠ technology-based services specialising in background and medical screening, provides the following update on trading for the six months ended 30 June 2020 and the impact of COVID-19.
As previously announced, having entered 2020 with its highest ever order book and a healthy pipeline, the COVID-19 outbreak impacted the Company’s business due to the widespread job losses and freeze on recruitment. However, ClearStar experienced a significant uptick in revenue run rate from the end of May, which has continued throughout June and into July 2020. As a result, revenue for the first half was $8.9m (H1 2019: $11.6m). The Company is pleased to report that revenue for June 2020 was 74% higher than for April 2020 and returned to the same level of revenue seen in February 2020. The growth in revenue from May is primarily from financial institutions preparing for a return to normal employment levels, business staffing companies as well as an increase in demand for Medical Information Services.
Xpediator 23.5p £33.3m (XPD.L)
Trading update for the six-month period ended 30 June 2020. The trading period has, like most of the world, been influenced by the global COVID-19 pandemic. The Group maintained the transportation of essential goods across the UK and Europe during the initial COVID-19 lock-down periods, with the Group now seeing transportation volumes moving back towards pre-COVID-19 levels.
As announced at the time of the final results, trading in the first three months was slightly up on a like for like basis and whilst trading was impacted as a result of lockdown, the Group has performed robustly during the pandemic with steady recovery since April. The Group’s trading has been assisted by the diversity of its European footprint and we have seen good performance in some of our Central and Eastern European countries that have not been as badly affected by the crisis. Activity in the logistics division has remained broadly stable and transportation services, after a natural period of reduced sales, are gathering momentum.
As a result, the business traded only marginally behind management’s original expectations for the six-month period to 30 June 2020.
Wey Education 25.3p £35m (WEY.L)
The online educational services group is pleased to update the market on current trading for the year ending 31 August 2020.
Trading has continued to be very positive since the publication of the group’s interim announcement in May and is in excess of expectations. Group turnover is expected to be in excess of £8m for the financial year ending on August 31, 2020, an anticipated growth of in excess of 30% from the previous year.
Group Profit Before Tax (after adjusting for share based payments and amortisation of acquired intangibles) is expected to exceed market expectations of £0.5m (2019:(£0.6m Loss)).
Goldstone Resources 7.15p £18m (GRL.L)
In line with progress towards commencing production at the Homase South Pit and construction of the associated heap leach facility, the Company has planned an additional infill RC drilling programme with the objective to increase the mineable resource at depth at the Homase South Pit, which is expected to commence shortly.
The proposed programme will seek to further define and extend the mineable resource down-dip at the Homase South Pit to a vertical depth of approximately 60 metres. As defined in the DEP, the Homase South Pit is currently targeting the oxide resource to a vertical depth of 30 metres. The programme will build on previous drilling completed by Goldstone in 2011-2012, which defined the Company’s existing JORC resource, and which indicated increased grades in this area of 1.4g/t to 2.5g/t below the weathered zone of 30 metres.
Metal Tiger 25p £38m (MTR.L)
The investor in natural resource opportunities, has subscribed for 7,142,857 new ordinary shares in Artemis Resources Limited at a price of A$0.07 per share for an investment cost of A$500,000 .
The Investment forms part of Artemis’ A$5.6 million fundraise announced earlier today. On completion of the Fundraise, Metal Tiger will be interested in 7,142,857 Artemis Shares, representing approximately 0.6% of Artemis’s then enlarged issued share capital.
Artemis is an ASX-listed (ASX:ARV) natural resource exploration and development company with a current focus on the Paterson and Carlow Castle gold projects in Western Australia. Mark Potter, Director and Chief Investment Officer of Metal Tiger, is Non-Executive Chairman of Artemis. For the half year ended 31 December 2019, Artemis reported net assets of A$54,173,585 and a net loss of A$8,051,108.
XL Media 26.5p £49.6m (XLM.L)
The global digital performance publisher, today announces it has completed a buy-out of the remaining interests of the founders in its premium website, 101GreatGoals.com . The consideration is not material in the context of the Group. The Company believes this simplified control structure will help accelerate the development of the Website in current and future geographies, including North America, where the opportunity is significant and growing.
101GreatGoals.com is a good example of the type of asset that XLMedia will concentrate on, as it consolidates and rebalances its publishing portfolio, with an emphasis on content-rich, highly engaging sites in regulated and high-potential markets.
In 2019, the vast majority of the Website’s revenue came from customer deals within the UK, while around 75% of the traffic to 101GreatGoals.com originated outside the UK.
Adamas Finance Asia 29p £29.8m (ADAM.L)
The Company focused on providing shareholders with attractive uncorrelated, risk adjusted returns from a diversified portfolio of pan-Asian investments, announced its open offer and placing , notice of General Meeting and proposed change of the Company’s name. The Company is proposing to undertake an Open Offer and Placing to raise £ 3,134,710 at 25p. The Company will also issue one Open Offer Warrant with each share with an exercise price of 40.0 pence and an exercise period of 3 years from and including the date of issue. The Company is also seeking shareholder approval to change its name to Jade Road Investments Limited.
The Company’s portfolio has undergone a transformation over the last few years and is seeking to establish an identity which more fully represents its pan-Asian small and medium-sized enterprise focus. Furthermore, the Board feels that this is an appropriate time for the Company’s name to reflect its Asian heritage while also acknowledging the wider investment scope which was adopted for its portfolio construction since May 2017. The Company’s new name reflects the spirit of connecting investors and capital from the West, across the Middle East and into the markets of the Far East.
Gattaca 49p £15.8m (GATC.L)
The UK’s leading specialist Engineering and Technology recruitment business, today provides the following trading update for the year ending 31 July 2020.
- Trading during April, May and June 2020, reflecting the impact of the UK Government measures due to COVID-19, has been 41% below last year
- Significant action taken to improve liquidity; the Group is now in a net cash position with strong working capital and liquidity. New covenants agreed with principal lender, HSBC, through to July 2021
- The Group-wide Improvement Plan has been accelerated, with particular focus on improving sales impact and client service, and on cost reduction
Verona Pharma 68.5p £73m (VRP.L)
The clinical-stage biopharmaceutical company focused on respiratory diseases, announces it has raised approximately $200 million (£159 million) in an oversubscribed private placement and subscription with new and existing institutional and accredited investor at a price of $4.50 per American Depositary Share and equivalent price per Ordinary Share, being £0.45 or $0.5625. Verona Pharma anticipates net proceeds of the Financing will be approximately $183 million after deducting placement agent fees and estimated expenses. Verona Pharma intends to use the net proceeds from the Financing primarily to fund its Phase 3 clinical program ENHANCE (Ensifentrine as a Novel inhaled Nebulized COPD therapy) in chronic obstructive pulmonary disease (COPD) and for general corporate purposes. The Phase 3 clinical trials are planned to start later in 2020.
0203 764 2344
*A corporate client of Hybridan LLP
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email firstname.lastname@example.org with “unsubscribe me”.